Our top pick for
Building a portfolio
Innate Pharma S.A is a biotechnology business based in the US. Innate Pharma S-A shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||USD$3.55 - USD$8.23|
|50-day moving average||USD$4.42|
|200-day moving average||USD$4.44|
|Wall St. target price||USD$7.35|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Innate Pharma S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innate Pharma S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Innate Pharma S-A's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Innate Pharma S-A shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Innate Pharma S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$38.3 million.
The EBITDA is a measure of a Innate Pharma S-A's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$70.5 million|
|Gross profit TTM||USD$11.8 million|
|Return on assets TTM||-3.27%|
|Return on equity TTM||-34.27%|
|Market capitalisation||USD$355.9 million|
TTM: trailing 12 months
There are currently 6,950 Innate Pharma S-A shares held short by investors – that's known as Innate Pharma S-A's "short interest". This figure is 7.5% down from 7,512 last month.
There are a few different ways that this level of interest in shorting Innate Pharma S-A shares can be evaluated.
Innate Pharma S-A's "short interest ratio" (SIR) is the quantity of Innate Pharma S-A shares currently shorted divided by the average quantity of Innate Pharma S-A shares traded daily (recently around 6435.1851851852). Innate Pharma S-A's SIR currently stands at 1.08. In other words for every 100,000 Innate Pharma S-A shares traded daily on the market, roughly 1080 shares are currently held short.
However Innate Pharma S-A's short interest can also be evaluated against the total number of Innate Pharma S-A shares, or, against the total number of tradable Innate Pharma S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Innate Pharma S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Innate Pharma S-A shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Innate Pharma S-A shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Innate Pharma S-A.
Find out more about how you can short Innate Pharma S-A stock.
We're not expecting Innate Pharma S-A to pay a dividend over the next 12 months.
Over the last 12 months, Innate Pharma S-A's shares have ranged in value from as little as $3.55 up to $8.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma S-A's is 0.2115. This would suggest that Innate Pharma S-A's shares are less volatile than average (for this exchange).
Innate Pharma S. A. , a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S. A.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.